Larissa S Carnevalli (Larissa Carnevalli)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 18

Top Venues

Nature communications

NPJ breast cancer

Journal for immunotherapy of cancer

Oncoimmunology

AstraZeneca R&D Cambridge

Universidade Federal de Sao Paulo Escola Paulista de Medicina (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

AstraZeneca R&D Cambridge May 01 2019

United Kingdom

Team Leader :: Bioscience, Oncology

AstraZeneca plc Jul 01 2013

United Kingdom

Associate Principal Scientist :: Oncology

Deutsches Krebsforschungszentrum

Germany

Senior postdoctoral fellow :: Stem Cells and Cancer

University of Cincinnati College of Medicine

United States

Postdoctoral Fellow :: Metabolic Disease Institute

Education History

Universidade Federal de Sao Paulo Escola Paulista de Medicina

Brazil

PHD :: Microbiology, Immunology and Parasitology

Publications

Elizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, Devon Taylor, Marta Milo, Chrysis Michaloglou, Adina M Hughes, Mimi Mai, Matthew King, Anisha Solanki, Lukasz Magiera, Ricardo Miragaia, Gozde Kar, Nathan Standifer, Michael Surace, Shaan Gill, Alison Peter, Sara Talbot, Sehmus Tohumeken, Henderson Fryer, Ali Mostafa, Kathy Mulgrew, Carolyn Lam, Scott Hoffmann, Daniel Sutton, Larissa S Carnevalli, Fernando J Calero-Nieto, Gemma N Jones, Andrew J Pierce, Zena Wilson, David Campbell, Lynet Nyoni, Carla P Martins, Tamara Baker, Gilberto Serrano de Almeida, Zainab Ramlaoui, Abdel Bidar, Benjamin Phillips, Joseph Boland, Sonia Iyer, J Carl Barrett, Arsene-Bienvenu Loembé, Serge Y Fuchs, Umamaheswar Duvvuri, Pei-Jen Lou, Melonie A Nance, Carlos Alberto Gomez Roca, Elaine B Cadogan, Susan E Critichlow, Steven Fawell, Mark Cobbold, Emma Dean, Viia Valge-Archer, Alan Lau, Dmitry I Gabrilovich, Simon T Barry
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. Nature communications 15 (1) (2024)
Elizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, Devon Taylor, Marta Milo, Chrysis Michaloglou, Adina M Hughes, Mimi Mai, Matthew King, Anisha Solanki, Lukasz Magiera, Ricardo Miragaia, Gozde Kar, Nathan Standifer, Michael Surace, Shaan Gill, Alison Peter, Sara Talbot, Sehmus Tohumeken, Henderson Fryer, Ali Mostafa, Kathy Mulgrew, Carolyn Lam, Scott Hoffmann, Daniel Sutton, Larissa S Carnevalli, Fernando J Calero-Nieto, Gemma N Jones, Andrew J Pierce, Zena Wilson, David Campbell, Lynet Nyoni, Carla P Martins, Tamara Baker, Gilberto Serrano de Almeida, Zainab Ramlaoui, Abdel Bidar, Benjamin Phillips, Joseph Boland, Sonia Iyer, J Carl Barrett, Arsene-Bienvenu Loembé, Serge Y Fuchs, Umamaheswar Duvvuri, Pei-Jen Lou, Melonie A Nance, Carlos Alberto Gomez Roca, Elaine B Cadogan, Susan E Critichlow, Steven Fawell, Mark Cobbold, Emma Dean, Viia Valge-Archer, Alan Lau, Dmitry I Gabrilovich, Simon T Barry
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. Nature communications 15 (1) (2024)
Elizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, Devon Taylor, Marta Milo, Chrysis Michaloglou, Adina M Hughes, Mimi Mai, Matthew King, Anisha Solanki, Lukasz Magiera, Ricardo Miragaia, Gozde Kar, Nathan Standifer, Michael Surace, Shaan Gill, Alison Peter, Sara Talbot, Sehmus Tohumeken, Henderson Fryer, Ali Mostafa, Kathy Mulgrew, Carolyn Lam, Scott Hoffmann, Daniel Sutton, Larissa S Carnevalli, Fernando J Calero-Nieto, Gemma N Jones, Andrew J Pierce, Zena Wilson, David Campbell, Lynet Nyoni, Carla P Martins, Tamara Baker, Gilberto Serrano de Almeida, Zainab Ramlaoui, Abdel Bidar, Benjamin Phillips, Joseph Boland, Sonia Iyer, J Carl Barrett, Arsene-Bienvenu Loembé, Serge Y Fuchs, Umamaheswar Duvvuri, Pei-Jen Lou, Melonie A Nance, Carlos Alberto Gomez Roca, Elaine B Cadogan, Susan E Critichlow, Steven Fawell, Mark Cobbold, Emma Dean, Viia Valge-Archer, Alan Lau, Dmitry I Gabrilovich, Simon T Barry
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. Nature communications 15 (1) (2024)
Lorna Hopcroft, Eleanor M Wigmore, Stuart Charles Williamson, Susana Ros, Cath Eberlein, Jennifer I Moss, Jelena Urosevic, Larissa S Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J A Goodwin, Brandon S Willis, Claire Rooney, Elza C de Bruin, Simon T Barry
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. NPJ breast cancer 9 (1) (2023)
Lorna Hopcroft, Eleanor M Wigmore, Stuart Charles Williamson, Susana Ros, Cath Eberlein, Jennifer I Moss, Jelena Urosevic, Larissa S Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J A Goodwin, Brandon S Willis, Claire Rooney, Elza C de Bruin, Simon T Barry
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. NPJ breast cancer 9 (1) (2023)
Mandy Lawson, Natalie Cureton, Susana Ros, Azadeh C Bashi, Jelena Urosevic, Sophie D'Arcy, Oona Delpuech, Michelle DuPont, David I Fisher, Eric T Gangl, Hilary J Lewis, Dawn Trueman, Neha Wali, Stuart Charles Williamson, Jennifer I Moss, Elodie Montaudon, Héloïse Derrien, Elisabetta Marangoni, Ricardo J Miragaia, Sladjana Gagrica, Pablo Morentin Gutierrez, Thomas Moss, Gareth A Maglennon, Daniel Sutton, Radoslaw Polanski, Alan Rosen, Jonathan Cairns, Pei Zhang, Mònica Sánchez-Guixé, Violeta Serra, Susan E Critchlow, James S Scott, Justin P O Lindemann, Simon T Barry, Teresa Klinowska, Christopher J Morrow, Larissa S Carnevalli
The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance. Cancer research (2023)
Lorna Hopcroft, Eleanor M Wigmore, Stuart Charles Williamson, Susana Ros, Cath Eberlein, Jennifer I Moss, Jelena Urosevic, Larissa S Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffman, Daniel Sutton, Stewart Jones, Richard J A Goodwin, Brandon S Willis, Claire Rooney, Elza C de Bruin, Simon T Barry
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. NPJ breast cancer 9 (1) (2023)
Elizabeth A Kuczynski, Giulia Morlino, Alison Peter, Anna M L Coenen-Stass, Jennifer I Moss, Neha Wali, Oona Delpuech, Avinash Reddy, Anisha Solanki, Charles Sinclair, Dinis Pedro Calado, Larissa S Carnevalli
A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability. EMBO molecular medicine 14 (6) (2022)
Alison Harrod, Chun-Fui Lai, Isabella Goldsbrough, Georgia M Simmons, Natasha Oppermans, Daniela B Santos, Balazs Győrffy, Rebecca C Allsopp, Bradley J Toghill, Kirsty Balachandran, Mandy Lawson, Christopher J Morrow, Manasa Surakala, Larissa S Carnevalli, Pei Zhang, David S Guttery, Jacqueline A Shaw, Raoul Charles Coombes, Lakjaya Buluwela, Simak Ali
Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer. Oncogene 41 (44) (2022)
Filipe Correia Martins, Dominique-Laurent Couturier, Ines de Santiago, Carolin Margarethe Sauer, Maria Vias, Mihaela Angelova, Deborah Sanders, Anna Piskorz, James Hall, Karen Hosking, Anumithra Amirthanayagam, Sabina Cosulich, Larissa S Carnevalli, Barry R Davies, Thomas B K Watkins, Ionut-Gabriel Funingana, Helen Bolton, Krishnayan Haldar, John Latimer, Peter Baldwin, Robin Crawford, Matthew D Eldridge, Bristi Basu, Mercedes Jimenez-Linan, Andrew W Mcpherson, Nicholas McGranahan, Kevin Litchfield, Sohrab P Shah, Iain A McNeish, Carlos Caldas, Gerard I Evan, Charles Swanton, James D Brenton
Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer. Nature communications 13 (1) (2022)
Alexey S Revenko, Larissa S Carnevalli, Charles Sinclair, Ben Johnson, Alison Peter, Molly Taylor, Lisa Hettrick, Melissa Chapman, Stephanie Klein, Anisha Solanki, Danielle Gattis, Andrew Watt, Adina M Hughes, Lukasz Magiera, Gozde Kar, Lucy Ireland, Deanna A Mele, Vasu Sah, Maneesh Singh, Josephine Walton, Maelle Mairesse, Matthew King, Mark Edbrooke, Paul Lyne, Simon T Barry, Stephen Fawell, Frederick W Goldberg, A Robert MacLeod
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer. Journal for immunotherapy of cancer 10 (4) (2022)
Dimitra Georgopoulou, Maurizio Callari, Oscar M Rueda, Abigail Shea, Alistair Martin, Agnese Giovannetti, Fatime Qosaj, Ali Dariush, Suet-Feung Chin, Larissa S Carnevalli, Elena Provenzano, Wendy Greenwood, Giulia Lerda, Elham Esmaeilishirazifard, Martin O'Reilly, Violeta Serra, Dario Bressan, null null, Gordon B Mills, H Raza Ali, Sabina S Cosulich, Gregory J Hannon, Alejandra Bruna, Carlos Caldas
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. Nature communications 12 (1) (2021)
Larissa S Carnevalli, Molly Ann Taylor, Matthew King, Anna M L Coenen-Stass, Adina M Hughes, Sigourney Bell, Theresa A Proia, Yanjun Wang, Antonio Ramos-Montoya, Neha Wali, Danielle Carroll, Maneesh Singh, Michele Moschetta, Pablo Morentin Gutierrez, Cristina Gardelli, Susan E Critchlow, Teresa Klinowska, Stephen E Fawell, Simon T Barry
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition. Molecular cancer therapeutics 20 (6) (2021)
Graham P Collins, Tracy N Clevenger, Kathleen A Burke, Buyue Yang, Alex MacDonald, David Cunningham, Christopher P Fox, Andre Goy, John Gribben, Grzegorz S Nowakowski, Mark J Roschewski, Julie M Vose, Anusha Vallurupalli, Jean Cheung, Amelia Raymond, Barrett Nuttall, Dan Stetson, Brian A Dougherty, Stein Schalkwijk, Larissa S Carnevalli, Brandon Willis, Lin Tao, Elizabeth A Harrington, Ahmed Hamdy, Raquel Izumi, J Elizabeth Pease, Melanie M Frigault, Ian Flinn
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies. Leukemia & lymphoma 62 (11) (2021)
Silvia Basilico, Xiaonan Wang, Alison Kennedy, Konstantinos Tzelepis, George Giotopoulos, Sarah J Kinston, Pedro M Quiros, Kim Wong, David J Adams, Larissa S Carnevalli, Brian James Patrick Huntly, George S Vassiliou, Fernando J Calero-Nieto, Berthold Göttgens
Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AML. Nature communications 11 (1) (2020)
Theresa A Proia, Maneesh Singh, Richard Woessner, Larissa S Carnevalli, Gayathri Bommakanti, Lukasz Magiera, Srimathi Srinivasan, Shaun Grosskurth, Michael P Collins, Chris Womack, Matthew Griffin, Minwei Ye, Susan Cantin, Deanna L Russell, Mingchao Xie, Adina M Hughes, Nanhua Deng, Deanna A Mele, Stephen Fawell, Simon T Barry, Corinne Reimer, J Carl Barrett, Patricia McCoon
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (23) (2020)
Sophie Langdon, Adina M Hughes, Molly Ann Taylor, Elizabeth A Kuczynski, Deanna A Mele, Oona Delpuech, Laura Jarvis, Anna Staniszewska, Sabina Cosulich, Larissa S Carnevalli, Charles Sinclair
Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. Oncoimmunology 7 (8) (2018)
Larissa S Carnevalli, Charles Sinclair, Molly A Taylor, Pablo Morentin Gutierrez, Sophie Langdon, Anna M L Coenen-Stass, Lorraine Mooney, Adina Hughes, Laura Jarvis, Anna Staniszewska, Claire Crafter, Ben Sidders, Elizabeth Hardaker, Kevin Hudson, Simon T Barry
PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity. Journal for immunotherapy of cancer 6 (1) (2018)

Larissa S Carnevalli.css-eqlu8i{font-size:small;padding-left:4px;} (Larissa Carnevalli)

Publication Activity (10 Years)

Top Topics

Top Venues

Larissa S Carnevalli (Larissa Carnevalli)